151 related articles for article (PubMed ID: 23994117)
1. Detection of MPL mutations by a novel allele-specific PCR-based strategy.
Furtado LV; Weigelin HC; Elenitoba-Johnson KS; Betz BL
J Mol Diagn; 2013 Nov; 15(6):810-8. PubMed ID: 23994117
[TBL] [Abstract][Full Text] [Related]
2. Screening for MPL mutations in essential thrombocythemia and primary myelofibrosis: normal Mpl expression and absence of constitutive STAT3 and STAT5 activation in MPLW515L-positive platelets.
Glembotsky AC; Korin L; Lev PR; Chazarreta CD; Marta RF; Molinas FC; Heller PG
Eur J Haematol; 2010 May; 84(5):398-405. PubMed ID: 20113333
[TBL] [Abstract][Full Text] [Related]
3. Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis.
Boyd EM; Bench AJ; Goday-Fernández A; Anand S; Vaghela KJ; Beer P; Scott MA; Bareford D; Green AR; Huntly B; Erber WN
Br J Haematol; 2010 Apr; 149(2):250-7. PubMed ID: 20151976
[TBL] [Abstract][Full Text] [Related]
4. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
[TBL] [Abstract][Full Text] [Related]
5. Identification of MPL W515L/K mutations in patients with primary myelofibrosis and essential thrombocythaemia by allele-specific polymerase chain reaction.
Daly S; Conneally E; Langabeer SE
Acta Haematol; 2009; 121(4):221-2. PubMed ID: 19521067
[No Abstract] [Full Text] [Related]
6. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
[TBL] [Abstract][Full Text] [Related]
7. A multiplexed fragment analysis-based assay for detection of JAK2 exon 12 mutations.
Furtado LV; Weigelin HC; Elenitoba-Johnson KS; Betz BL
J Mol Diagn; 2013 Sep; 15(5):592-9. PubMed ID: 23810504
[TBL] [Abstract][Full Text] [Related]
8. JAK2 V617F and MPL W515L/K mutations in Korean patients with essential thrombocythemia.
Kim HJ; Jang JH; Yoo EH; Kim HJ; Ki CS; Kim JW; Kim SH
Korean J Lab Med; 2010 Oct; 30(5):474-6. PubMed ID: 20890078
[TBL] [Abstract][Full Text] [Related]
9. Expanded molecular detection of MPL codon p.W515 and p.S505N mutations in myeloproliferative neoplasms.
Miller EW; Lamberson CM; Akabari RR; Nasr MR; Sperber SM
J Clin Lab Anal; 2023 Dec; 37(23-24):e24992. PubMed ID: 38058281
[TBL] [Abstract][Full Text] [Related]
10. MPL exon 10 mutations other than canonical MPL W515L/K mutations identified by in-house MPL exon 10 direct sequencing in essential thrombocythemia.
Sugimoto Y; Nagaharu K; Ohishi K; Nakamura M; Ikejiri M; Nakatani K; Mizutani M; Tamaki S; Ikeda T; Tawara I; Katayama N
Int J Hematol; 2021 May; 113(5):618-621. PubMed ID: 33770389
[TBL] [Abstract][Full Text] [Related]
11. MPL mutation profile in JAK2 mutation-negative patients with myeloproliferative disorders.
Ma W; Zhang X; Wang X; Zhang Z; Yeh CH; Uyeji J; Albitar M
Diagn Mol Pathol; 2011 Mar; 20(1):34-9. PubMed ID: 21326037
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of MPL W515L/K mutations in Taiwanese patients with Philadelphia-negative chronic myeloproliferative neoplasms.
Lieu CH; Shen YJ; Lai WC; Tsai WH; Hsu HC
J Chin Med Assoc; 2010 Oct; 73(10):530-2. PubMed ID: 21051030
[TBL] [Abstract][Full Text] [Related]
13. Increased frequency of co-existing JAK2 exon-12 or MPL exon-10 mutations in patients with low JAK2(V617F) allelic burden.
Nussenzveig RH; Pham HT; Perkins SL; Prchal JT; Agarwal AM; Salama ME
Leuk Lymphoma; 2016; 57(6):1429-35. PubMed ID: 26419289
[TBL] [Abstract][Full Text] [Related]
14. MPL W515L/K mutations in 343 Chinese adults with JAK2V617F mutation-negative chronic myeloproliferative disorders detected by a newly developed RQ-PCR based on TaqMan MGB probes.
Ruan GR; Jiang B; Li LD; Niu JH; Li JL; Xie M; Qin YZ; Liu YR; Huang XJ; Chen SS
Hematol Oncol; 2010 Mar; 28(1):33-9. PubMed ID: 19274616
[TBL] [Abstract][Full Text] [Related]
15. Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia.
Dos Santos LC; Ribeiro JC; Silva NP; Cerutti J; da Silva MR; Chauffaille Mde L
Rev Bras Hematol Hemoter; 2011; 33(6):417-24. PubMed ID: 23049357
[TBL] [Abstract][Full Text] [Related]
16. Development of a Real-Time qPCR Assay for Detection of Common MPL Mutations in Myeloproliferative Neoplasms (MPNS).
Ullah N; Khan SN; Umair M; Khan AA; Liu X; Khattak AA; Yousafzai YM
Appl Biochem Biotechnol; 2022 Dec; 194(12):5907-5917. PubMed ID: 35838887
[TBL] [Abstract][Full Text] [Related]
17. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.
Beer PA; Campbell PJ; Scott LM; Bench AJ; Erber WN; Bareford D; Wilkins BS; Reilly JT; Hasselbalch HC; Bowman R; Wheatley K; Buck G; Harrison CN; Green AR
Blood; 2008 Jul; 112(1):141-9. PubMed ID: 18451306
[TBL] [Abstract][Full Text] [Related]
18. The analysis of JAK2 and MPL mutations and JAK2 single nucleotide polymorphisms in MPN patients by MassARRAY assay.
Zhang SJ; Qiu HX; Li JY; Shi JY; Xu W
Int J Lab Hematol; 2010 Aug; 32(4):381-6. PubMed ID: 20331763
[TBL] [Abstract][Full Text] [Related]
19. JAK2 GGCC haplotype in MPL mutated myeloproliferative neoplasms.
Pietra D; Casetti I; Da Vià MC; Elena C; Milanesi C; Rumi E
Am J Hematol; 2012 Jul; 87(7):746-7. PubMed ID: 22565617
[TBL] [Abstract][Full Text] [Related]
20. JAK2 and MPL gene mutations in V617F-negative myeloproliferative neoplasms.
Siemiatkowska A; Bieniaszewska M; Hellmann A; Limon J
Leuk Res; 2010 Mar; 34(3):387-9. PubMed ID: 19643476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
